Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
Long-Term Follow-Up Study of Patients who were Treated with Lethally-Irradiated GM-CSF–Transduced Allogeneic Prostate Cancer Cell Vaccine (Prostate GVAX)
Protocol Number:
J1286
Phase:
NULL
Physician:
Emmanuel Antonarakis
Purpose:
To follow-up with subjects who received a gene therapy that is to be evaluated once per year, To identify and characterize any potential long-term adverse events that may be associated with this therapy
Eligibility:
All research subjects who have participated in clinical trials of Prostate GVAX, are declared off-study from an interventional clinical trial of Prostate GVAX, must have received at least one dose of the Prostate GVAX vaccine at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
Treatment:
Visits to the clinic one year after the last dose of GVAX for Physical exam, blood work and potential CT or bone scans and continuing annually for a total of 3 annual visits.
Population:
Adult
Last Update
11/26/2014 04:10 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.